Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (mCRC): An agestratified analysis.

被引：0
|
作者：
Vassilev, Zdravko
Fan, Xiaozhou
Ostojic, Helene
Xu, Julie
Barzi, Afsaneh
机构：
[1] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[2] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
64
引用
收藏
页码：64 / 64
页数：1
相关论文
共 50 条
  • [31] FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer A Systematic Review and Pooled Analysis
    Tomasello, Gianluca
    Petrelli, Fausto
    Ghidini, Michele
    Russo, Alessandro
    Passalacqua, Rodolfo
    Barni, Sandro
    JAMA ONCOLOGY, 2017, 3 (07)
  • [32] Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
    Shui, Lin
    Wu, Yu-Shen
    Lin, Huapeng
    Shui, Pixian
    Sun, Qin
    Chen, Xiaopin
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 48 (05) : 1870 - 1881
  • [33] FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO
    Cremolini, C.
    Rossini, D.
    Antoniotti, C.
    Pietrantonio, F.
    Lonardi, S.
    Salvatore, L.
    Marmorino, F.
    Borelli, B.
    Ambrosini, M.
    Barsotti, G.
    Di Stefano, B.
    Masi, G.
    Boccaccino, A.
    Tamberi, S.
    Tamburini, E.
    Frassineti, L. G.
    Simionato, F.
    Fontanini, G.
    Boni, L.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1294 - S1295
  • [34] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [35] FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF BRAF MUTANT METASTATIC COLORECTAL CANCER PATIENTS
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    ANNALS OF ONCOLOGY, 2012, 23 : 93 - 93
  • [36] Comparison of safety and efficacy of fluorouracil plus oxaliplatin plus irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice
    Kazama, Keisuke
    Shiozawa, Manabu
    Numata, Masakatsu
    Sugano, Nobuhiro
    Sato, Sumito
    Uchiyama, Mamoru
    Sato, Maho
    Aoyama, Toru
    Tamagawa, Hiroshi
    Oshima, Takashi
    Yukawa, Norio
    Rino, Yasushi
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2022, 37 (02) : 337 - 348
  • [37] FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial
    Falcone, A.
    Cremolini, C.
    Loupakis, F.
    Lonardi, S.
    Casagrande, M. E.
    Murgioni, S.
    Salvatore, L.
    Masi, G.
    Fanotto, V.
    Granetto, C.
    Marmorino, F.
    Ginocchi, L.
    Ziampiri, S.
    Grande, R.
    Tonini, G.
    Delfanti, S.
    Di Donato, S.
    Fontanini, G.
    Boni, L.
    Zagonel, V.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] A phase II study of FOLFOXIRI plus bevacizumab (Bmab) as initial chemotherapy for patients (pts) with untreated metastatic colorectal cancer (mCRC): TRICC1414 (Be TRI)
    Yamada, Takeshi
    Nishina, Tomohiro
    Nasu, Junichiro
    Matsumoto, Toshihiko
    Yuasa, Yasuhiro
    Shiraishi, Takeshi
    Nagano, Hiroaki
    Moriyama, Ichiro
    Fujiwara, Toshiyoshi
    Miguchi, Masashi
    Yoshida, Ryosuke
    Nosaka, Kimiyasu
    Tanioka, Hiroaki
    Nagasaka, Takeshi
    Kurisu, Yasuro
    Kobayashi, Michiya
    Tsuchihashi, Kenji
    Inukai, Michio
    Kikuchi, Takashi
    Shinozaki, Katsunori
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [39] KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
    Salvatore, L.
    Loupakis, F.
    Fontanini, G.
    Cremolini, C.
    Stasi, I.
    Fabbri, A.
    Ciarlo, A.
    Granetto, C.
    Basolo, F.
    Falcone, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 339 - 339
  • [40] KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Salvatore, L.
    Loupakis, F.
    Cremolini, C.
    Lupi, C.
    Masi, G.
    Sensi, E.
    Stasi, I
    Fornaro, L.
    Vasile, E.
    Schirripa, M.
    Truscelli, K.
    Giannini, R.
    Baldi, G. G.
    Altavilla, A.
    Ciarlo, A.
    Granetto, C.
    Fea, E.
    Fontanini, G.
    Basolo, F.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20
12345